Key Insights

Highlights

Treatment Research

3 treatments under study, led by Switching To Low Dose Emicizumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Active Not Recruiting1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07830693Not Yet RecruitingPrimary

Efanesoctocog Prophylaxis Or The Optimization Of Treatment: Real-World Experience Of Taylorizing Clotting Therapy In Hemophilia A

NCT07439055Phase 2/3Active Not RecruitingPrimary

Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

Showing all 2 trials

Research Network

Common Treatments

  • Switching To Low Dose Emicizumab1
  • Study Questionnaires1
  • Clinicalpharmacological Data Collection1

Active Sponsors

  • Chulalongkorn University1
  • Nantes University Hospital1

Top Investigators

Activity Timeline